Simplification of antiretroviral treatment;Simplificación del tratamiento antirretroviral

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 20, Issue SUPPL.2, 2002, Pages 48-57

  Ribera, Esteban ^a   Aguirrebengoa, Koldo ^b   Miralles, Celia ^c   Antela, Antonio ^d   Rivero, Antonio ^e   Arribas, José Ramón ^f  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

^c HOSPITAL XERAL CÍES   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^f HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Adherence; Antiretroviral therapy; Simplification

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANTIVIRAL THERAPY; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; INFECTION CONTROL; LIFESTYLE; MAINTENANCE THERAPY; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; REVIEW; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; TREATMENT PLANNING; TREATMENT RESPONSE; VIROLOGY; VIRUS LOAD;

EID: 2342660420     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-60.
2. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
3. Wong JK, Hazareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. Recovery of replication-competent HIV despite prolonged suppression of HIV viremia. Science 1997;278:1211-5.
4. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-13.
5. Furtado M, Callaway DS, Phair JP, Wit F, Weigel HM, Ten Kate RW, et al. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-22.
6. Miró JM, Antela A, Arrizabalaga J, Clotet B, Gatell JM, Guerra L, et al. Recomendaciones de GESIDA/PNS respecto al tratamiento antirretroviral en pacientes adultos infectados por el VIH en el año 2000. Enferm Infecc Microbiol Clin 2000;18:329-51.
7. Fätkenheuer G, Theisen A, Rockstroh J, Grabow T, Wicke C, Becker K, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997;11:F111-6.
8. Ferrer E, Consiglio E, Podzamczer, Grau I, Ramon JM, Perez JL, et al. Analysis of the discontinuation of protease inhibitor therapy in routine clinical practice. Scand J Infect Dis 1999;31:495-9.
9. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3.
10. Knobel H, Codina C, Miró JM, Carmona A, Garcia B, Antela A, et al. Recomendaciones GESIDA/SEFH/PNS para mejorar la adherencia al tratamiento antirretroviral. Enf Infecc Microbiol Clin 2000;18:27-39.
11. th European Conference on Clinical Aspects and Treatment of HIV-infection, 1999.
12. th Conference on Retroviruses and Opportunistic Infections, 2000.
13. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaud JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients. N Engl J Med 1998;339:1269-76.
14. Havlir DV, Marschner IC, Hirsch MS, Colier AC, Tebas P, Bassett R, et al. Maintenance antiretroviral therapies in HIV-1 infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998;339:1261-8.
15. Reijers MH, Weverling GJ, Jurriaans S, Meiffredy V. Flanche P, Gastaud JA, et al. Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam duration of antiretroviral medication (ADAM) study. Lancet 1998;352:185-90.
16. Cooper DA. Therapeutic strategies for HIV infection. Time to think hard. N Engl J Med 1998;339:1319-21.
17. Manfredi R, Chiodo F. Switch to an antiretroviral treatment of expected lower potency after effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000;23:95-8.
18. Reijers MH, Weverling GJ, Jurriaans S, Weigel HM, Ten Kate RW, Mulder JW, et al. The the ADAM study: maintenance therapy after 50 weeks of induction therapy. Durban, XIII International Conference on AIDS, 2000.
19. th European Conference on Clinical Aspects and treatment of HIV-infection, 2001.
20. th Conference on Retrovirus and Opportunistis Infections, 2001.
21. Katlama C, Stazewsky S, Clumeck N, Arasteh K, Dellamonica P, Molina JM, et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-RNA: results of a prospective, randomized, multicenter, open label study (DMP 006-027). Durban, XIII International AIDS Conference, 2000.
22. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz C, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with HIV infection and long-lasting viral suppression. Clin Infect Dis 2002;34:504-10.
23. st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001.
24. Barreiro P, Soriano V, Blanco F, Casimiro C, De la Cruz JJ, Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000;14:807-12.
25. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr 2001;27:229-36.
26. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-26.
27. st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001.
28. th Conference on Retroviruses and Opportunistic Infections, 2000.
29. th Annual Meeting of the Infectious Disease Society of America, 2001.
30. th Conference on Retrovirus and Opportunistis Infections, 2002.
31. th Conference on Retrovirus and Opportunistis Infections, 2002.
32. Hirschel B, Flepp M, Bucherc HC, Zellweger C, Telenti A, Wagels T, et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002;16:381-5.
33. th Conference on Retroviruses and Opportunistic Infections, 2001.
34. th European Conference on Clinical Aspects and Treatment of HIV Infection, 2001.
35. th European Conference on Clinical Aspects and Treatment of HIV Infection, 2001.
36. th International AIDS Conference, 2000.
37. Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Kramtz V, Mautort E, et al. Efavirenz as a substitute for protease inhibitors in HIV-1 Infected patients with undetectable plasma viral load on HAART: A median follow-up of 64 weeks. J Acquir Immune Defic Syndr 2001;27:459-62.
38. st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000.
39. th International AIDS Conference, 2000.
40. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999;13:805-10.
41. th Conference on Retroviruses and Opportunistic Infections, 2000.
42. th International AIDS Conference, 2000.
43. Luca A, Baldini F, Cingolani A, Giambenedetto S, Zaccarelli M, Tozzi V, et al. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. AIDS 2000;14:1655-6.
44. th Conference on Retroviruses and Opportunistic Infections, 2000.
45. th International AIDS Conference, 2000.
46. th International AIDS Conference, 2000.
47. th International AIDS Conference, 2000.
48. Dieleman JP, Gyssens IC, Sturkenboom MCJM, Niesters HGM, Ende ME. Substituting nevirapine for protease inhibitors because of intolerance. AIDS 1999;13:1423-4.
49. th European Conference on Clinical Aspects and Treatment of HIV-Infection, 1999.
50. Rabassa B (coordinador del programa de apoyo al cumplimiento terapéutico antirretroviral). Infección por VIH y cumplimiento del tratamiento antirretroviral en España. Madrid, 1999.
51. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23:1296-310.
52. th Conference on Retroviruses and Opportunistic Infections, 2001.
53. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A. Nevirapine/didanosine/lamivudine once daily in HIV-infected intravenous drug users. Antiviral Therapy 1998;3:55-6.
54. Maggiolo F, Migliorino M, Maserati R, Pan A, Rizzi M, Provettoni G, et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001;6:249-53.
55. th Conference on Retroviruses and Opportunistic Infections, 2002.
56. Felipe G, Hernando K, Antonia SM, Arrizabalaga J, Aranda M, Romeu J, et al. Comparison of twice-daily satavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV-infection: the Scan study. AIDS 2000;14:2485-94.
57. Van Heeswijk RPG, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000;14: F77-F82.
58. th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999.
59. th Conference on Retroviruses and Opportunistic Infections, 2002.
60. th Conference on Retroviruses and Opportunistic Infections, 2002.
61. Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, et al. Pharmacodynamics of abacavir in an in vitro Hollow-Fiber model system. Antimicrob Agents Chemother 2002;46:464-70.
62. th Conference on Retroviruses and Opportunistic Infections, 2001.
63. Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, et al. Prototype trial design for rapid dose selection of antiretroviral drugs: an example using emtricitabine (Coviracil). J Antimicrob Chemother 2001;48:507-13.
64. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602.
65. Rosenbach KA, Allison R, Nadler JP. Daily dosing of highly active antiretroviral therapy. Clin Infect Dis 2002;34:686-92.
66. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999;341:1865-73.